The ClinGen Evidence Repository is an **FDA-recognized human genetic variant database** containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

Variant: NM_000546.5(TP53):c.818G>A (p.Arg273His)

Version: 1.1

CA000434

12366 (ClinVar)

Gene: TP53 (HGNC:7157)
Condition: Li-Fraumeni syndrome (MONDO:0018875)
Inheritance Mode: Autosomal dominant inheritance
UUID: 8d32df42-16ac-41f2-9bf1-e2b9ce206190
Approved on: 2024/8/5
Published on: 2024/8/5

HGVS expressions

NM_000546.5:c.818G>A
NM_000546.5(TP53):c.818G>A (p.Arg273His)
NC_000017.11:g.7673802C>T
CM000679.2:g.7673802C>T
NC_000017.10:g.7577120C>T
CM000679.1:g.7577120C>T
NC_000017.9:g.7517845C>T
NG_017013.2:g.18749G>A
ENST00000503591.2:c.818G>A
ENST00000508793.6:c.818G>A
ENST00000509690.6:c.422G>A
ENST00000514944.6:c.539G>A
ENST00000604348.6:c.797G>A
ENST00000269305.9:c.818G>A
ENST00000269305.8:c.818G>A
ENST00000359597.8:c.818G>A
ENST00000413465.6:c.782+379G>A
ENST00000420246.6:c.818G>A
ENST00000445888.6:c.818G>A
ENST00000455263.6:c.818G>A
ENST00000504290.5:c.422G>A
ENST00000504937.5:c.422G>A
ENST00000509690.5:c.422G>A
ENST00000510385.5:c.422G>A
ENST00000610292.4:c.701G>A
ENST00000610538.4:c.701G>A
ENST00000610623.4:c.341G>A
ENST00000615910.4:c.785G>A
ENST00000617185.4:c.818G>A
ENST00000618944.4:c.341G>A
ENST00000619186.4:c.341G>A
ENST00000619485.4:c.701G>A
ENST00000620739.4:c.701G>A
ENST00000622645.4:c.701G>A
ENST00000635293.1:c.701G>A
NM_001126112.2:c.818G>A
NM_001126113.2:c.818G>A

NM_001126114.2:c.818G>A
NM_001126115.1:c.422G>A
NM_001126116.1:c.422G>A
NM_001126117.1:c.422G>A
NM_001126118.1:c.701G>A
NM_001276695.1:c.701G>A
NM_001276696.1:c.701G>A
NM_001276697.1:c.341G>A
NM_001276698.1:c.341G>A
NM_001276699.1:c.341G>A
NM_001276760.1:c.701G>A
NM_001276761.1:c.701G>A
NM_001276695.2:c.701G>A
NM_001276696.2:c.701G>A
NM_001276697.2:c.341G>A
NM_001276698.2:c.341G>A
NM_001276699.2:c.341G>A
NM_001276760.2:c.701G>A
NM_001276761.2:c.701G>A
NM_000546.6:c.818G>A
NM_001126112.3:c.818G>A
NM_001126113.3:c.818G>A
NM_001126114.3:c.818G>A
NM_001126115.2:c.422G>A
NM_001126116.2:c.422G>A
NM_001126117.2:c.422G>A
NM_001126118.2:c.701G>A
NM_001276695.3:c.701G>A
NM_001276696.3:c.701G>A
NM_001276697.3:c.341G>A
NM_001276698.3:c.341G>A
NM_001276699.3:c.341G>A
NM_001276760.3:c.701G>A
NM_001276761.3:c.701G>A

Pathogenic

Met criteria codes 7

PP4_Moderate PS2 PS3 PS4 PP3 PM1 PM2_Supporting

Not Met criteria codes 7

PS1 BA1 PM5 BS1 BS3 BS2 BP4

Evidence Links 0

Expert Panel

TP53 VCEP

Criteria Specification Information

- **Criteria Specification:** *ClinGen TP53 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for TP53 Version 2.0.0*
- **Criteria Specification Approval History**
- **Criteria Specifications for this VCEP**

Evidence submitted by expert panel

TP53 VCEP

The NM_000546.6: c.818G>A variant in TP53 is a missense variant predicted to cause substitution of arginine by histidine at amino acid 273 (p.R273H). This variant has been reported in numerous unrelated probands meeting Classic LFS and Revised Chompret criteria. Based on this evidence, this variant scores 8 total points meeting the TP53 VCEP phenotype scoring criteria of ≥ 8 points. (PS4_Very Strong; PMIDs, 16401470, 15390294, 9242456, 10864200, 1565144, 7732013; SCV000186052.8). This variant has been identified as a de novo occurrence with confirmed parental relationships in 1 individual with an LFS-associated cancer totaling 4 phenotype points (PS2; PMID: 1267231). At least two individuals with this variant were found to have a variant allele fraction of 5-25%, which is a significant predictor of variant pathogenicity (PP4_Moderate, PMID: 34906512, SCV000186052.8). This variant has an allele frequency of 0.00001186 (14/1179946 alleles) in the European (non-Finnish) population in gnomAD v4.1.0 which is lower than the Clingen TP53 VCEP threshold (<0.00004) for PM2_Supporting, and therefore meets this criterion (PM2_Supporting). In vitro assays performed in yeast and/or human cell lines showed non-functional transactivation and loss of growth suppression activity indicating that this variant impacts protein function (PS3; PMIDs: 12826609, 30224644, 29979965). This variant resides within a codon (NM_00546.4: 273) of TP53 that is defined as a mutational hotspot by the ClinGen TP53 VCEP (PM1; PMID: 8023157). Computational predictor scores (BayesDel = 0.52; Align GVGD = Class 25) are above recommended thresholds (BayesDel > 0.16 and an Align GVGD Class of > 15), evidence that correlates with impact to TP53 via protein change (PP3). In summary, this variant meets the criteria to be classified as pathogenic for Li Fraumeni Syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen TP53 VCEP: PS4_Very Strong, PS2, PM2_Supporting, PS3, PP4_Moderate, PM1, PP3. (Bayesian Points: 22; VCEP specifications version 2.0; 7/24/2024).

Met criteria codes

PP4_Moderate	✔	At least two individuals with this variant were found to have a variant allele fraction of 5-25%, which is a significant predictor of variant pathogenicity (PP4_Moderate, PMID: 34906512, SCV000186052.8).
PS2	✔	This variant has been identified as a de novo occurrence with confirmed parental relationships in 1 individual with an LFS-associated cancer totaling 4 phenotype points (PS2; PMID: 1267231).
PS3	✔	In vitro assays performed in yeast and/or human cell lines showed non-functional transactivation and loss of growth suppression activity indicating that this variant impacts protein function (PS3; PMIDs: 12826609, 30224644, 29979965).
PS4	✔	PS4_VERY STRONG APPLIED This variant has been reported in numerous unrelated probands meeting Classic LFS and Revised Chompret criteria. Based on this evidence, this variant scores 8 total points meeting the TP53 VCEP phenotype scoring criteria of ≥ 8 points. (PS4_Very Strong; PMIDs, 16401470, 15390294, 9242456, 10864200, 1565144, 7732013; SCV000186052.8)
PP3	✔	Computational predictor scores (BayesDel = 0.52; Align GVGD = Class 25) are above recommended thresholds (BayesDel > 0.16 and an Align GVGD Class of > 15), evidence that correlates with impact to TP53 via protein change (PP3).
PM1	✔	This variant resides within a codon (NM_00546.4: 273) of TP53 that is defined as a mutational hotspot by the ClinGen TP53 VCEP (PM1; PMID: 8023157)
PM2_Supporting	✔	This variant has an allele frequency of 0.00001186 (14/1179946 alleles) in the European (non-Finnish) population in gnomAD v4.1.0 which is lower than the Clingen TP53 VCEP threshold (<0.00004) for PM2_Supporting, and therefore meets this criterion (PM2_Supporting).

Not Met criteria codes

PS1		✖	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BA1		✖	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM5		✖	5 different missense variants (p.Arg273Leu; p.Arg273Pro; p.Arg273Gly; p.Arg273Ser; p.Arg273Cys) in the same codon have been reported (ClinVar Variation IDs: 376655, 231060, 634682, 376656, 43594). However, the variants have not yet been curated to determine if they would be classified as pathogenic or likely pathogenic by the ClinGen TP53 VCEP's specifications (PM5 not evaluated).
BS1		✖	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS3		✖	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS2		✖	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP4		✖	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline

Curation History

Showing 1 to 2 of 2 rows

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.

ClinGen Terms of Use.
¤ Powered by BCM's Genboree.